Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225447 | 0.99 | RAB9A (0.42) | ALDH1A1RECQLRAB9AGLAKMT2A | |
| SCHEMBL30206621 | 0.99 | RAB9A (0.42) | ALDH1A1RECQLRAB9AGLAKMT2A | |
| Bromide SCHEMBL1194277 | 0.98 | GLA (0.42) | ALDH1A1RECQLRAB9AGLAKMT2A | |
| Hydrochloric Acid SCHEMBL28477049 | 0.98 | RAB9A (0.41) | ALDH1A1RECQLRAB9AGLAKMT2A | |
| Bromide SCHEMBL29494160 | 0.98 | GLA (0.42) | ALDH1A1RECQLRAB9AGLAKMT2A | |
| SCHEMBL8276407 | 0.90 | RAB9A (0.40) | ALDH1A1RECQLRAB9AKMT2ALMNA | |
| SCHEMBL1194250 | 0.87 | RAB9A (0.40) | ALDH1A1RECQLRAB9AGLAKMT2A | |
| Bromide SCHEMBL1194286 | 0.86 | ALDH1A1 (0.40) | ALDH1A1RECQLRAB9AGLAKMT2A | |
| SCHEMBL6227347 | 0.85 | RAB9A (0.59) | ALDH1A1RAB9AGLAKMT2ALMNA | |
| SCHEMBL6226248 | 0.85 | RAB9A (0.40) | ALDH1A1RAB9AKMT2ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034413-A1 | METHODS FOR DECELLULARIZING ANIMAL TISSUE AND BIOINKS DERIVED THEREFROM | VIRGINIA COMMONWEALTH UNIVERSITY | 2025-01-30 | — | — | US | claimed |
| WO-2023107410-A1 | METHODS FOR DECELLULARIZING ANIMAL TISSUE AND BIOINKS DERIVED THEREFROM | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2022238921-A1 | IN-SITU SYNTHESIS OF 3-SUBSTITUTED PYRIDINIUM COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2022-11-17 | — | — | WO | claimed |
| US-10717727-B2 | Pyridinium compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2020-07-21 | — | — | US | claimed |
| US-20190169175-A1 | NOVEL PYRIDINIUM COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2019-06-06 | — | — | US | claimed |
| US-10233175-B2 | Pyridinium compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2019-03-19 | — | — | US | claimed |
| US-20180118728-A1 | NOVEL PYRIDINIUM COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-03 | — | — | US | claimed |
| EP-3280711-A1 | NOVEL PYRIDINIUM COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162785-A1 | NOVEL PYRIDINIUM COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2016-10-13 | — | — | WO | claimed |
| EP-2659933-A1 | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | Torrent Pharmaceuticals Ltd. (IN) | 2013-11-06 | — | — | EP | claimed |
| JP-2011510067-A | — | — | 2011-03-31 | — | — | JP | claimed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | claimed |
| EP-2254563-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC | Torrent Pharmaceuticals Ltd. (IN) | 2010-12-01 | — | — | EP | claimed |
| WO-2009093264-A2 | PHARMACEUTICAL COMBINATIONS | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-07-30 | — | — | WO | claimed |
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | claimed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | claimed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | claimed |
| EP-1243581-A1 | Pyridinium compounds useful for the treatment of AGE-related diseases | Torrent Pharmaceuticals Ltd (IN) | 2002-09-25 | — | — | EP | claimed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | claimed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118728-A1 | NOVEL PYRIDINIUM COMPOUNDS | CYP3A5, MAPT, PLPBP | ALDH1A1 2469/4885RECQL 1534/4885RAB9A 3005/4885 |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | ALDH1A1 769/4885RECQL 131/4885RAB9A 1702/4885 |
| US-20190169175-A1 | NOVEL PYRIDINIUM COMPOUNDS | CYP3A5, MAPT, PLPBP | ALDH1A1 2469/4885RECQL 1534/4885RAB9A 3005/4885 |
| US-20030032660-A1 | Breaking preformed AGE | AGER, GPX1, RBP1 | ALDH1A1 1451/4885RECQL 186/4885RAB9A 2750/4885 |
| US-10717727-B2 | Pyridinium compounds | CYP3A5, PLPBP, PDXK | ALDH1A1 2279/4885RECQL 1644/4885RAB9A 3699/4885 |
| US-10233175-B2 | Pyridinium compounds | CYP3A5, PLPBP, PDXK | ALDH1A1 2279/4885RECQL 1644/4885RAB9A 3699/4885 |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | ALDH1A1 662/4885RECQL 747/4885RAB9A 4618/4885 |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | AGER, F12, DPP4 | ALDH1A1 528/4885RECQL 1098/4885RAB9A 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.